Want to see HK:1312 full AI Analyst Report?
1312 Stock Chart & Stats
HK$0.03
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$0.03
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.02 - HK$0.05
Previous CloseN/A
Volume162.00K
Average Volume (3M)9.95M
Market Cap
HK$167.36M
Enterprise ValueHK$299.40M
Total Cash (Recent Filing)HK$66.06M
Total Debt (Recent Filing)HK$203.68M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding5,588,572,000
10 Day Avg. Volume1,701,000
30 Day Avg. Volume9,954,100
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.18
P/FCF Ratio3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently high gross margins (49%–58%) indicate durable pricing power or a favorable product mix. This structural margin cushion helps absorb SG&A or cyclical pressure, supporting long-term cash generation and strategic flexibility even if operating profits lag.
Improving Cash GenerationPositive and improving operating and free cash flow, with a notable ~65% FCF step-up in 2025, strengthens funding for operations and capex without external financing. Sustainable cash conversion would materially improve resilience and execution over the next several quarters.
Reduced LeverageLower debt-to-equity (down to ~0.30–0.37) materially reduces financial risk and interest burden, increasing flexibility to weather earnings volatility. Improved leverage supports longer-term stability and optionality for investment or restructuring if needed.
Bears Say
Negative Operating ProfitabilityPersistent negative EBIT/EBITDA and a ~-47% net margin in 2025 signal structural weakness in operating economics. If operating losses persist, they will erode equity and constrain reinvestment, making long-term recovery and sustainable profitability harder to achieve.
Equity Erosion And Very Low ROESharp equity declines and a ~-77% ROE in 2025 point to value destruction. This undermines investor capital, may hamper capital raising, and increases the risk that recurring losses force restructuring or asset sales if profitability does not normalize soon.
Volatile Revenue And Weak Operating LeverageHigh revenue volatility (small 2024 growth then ~258% in 2025) suggests uneven demand or one-off drivers. Coupled with negative operating margins, the company shows poor operating leverage: revenue swings fail to translate into stable profits, raising medium-term execution risk.
Kontafarma China Holdings Ltd News
1312 FAQ
What was Kontafarma China Holdings Ltd’s price range in the past 12 months?
Kontafarma China Holdings Ltd lowest stock price was HK$0.02 and its highest was HK$0.05 in the past 12 months.
What is Kontafarma China Holdings Ltd’s market cap?
Kontafarma China Holdings Ltd’s market cap is HK$167.36M.
When is Kontafarma China Holdings Ltd’s upcoming earnings report date?
Kontafarma China Holdings Ltd’s upcoming earnings report date is Aug 31, 2026 which is in 51 days.
How were Kontafarma China Holdings Ltd’s earnings last quarter?
Kontafarma China Holdings Ltd released its earnings results on Mar 27, 2026. The company reported -HK$0.026 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.026.
Is Kontafarma China Holdings Ltd overvalued?
According to Wall Street analysts Kontafarma China Holdings Ltd’s price is currently Overvalued.
Does Kontafarma China Holdings Ltd pay dividends?
Kontafarma China Holdings Ltd pays a Annually dividend of HK$0.004 which represents an annual dividend yield of N/A. See more information on Kontafarma China Holdings Ltd dividends here
What is Kontafarma China Holdings Ltd’s EPS estimate?
Kontafarma China Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kontafarma China Holdings Ltd have?
Kontafarma China Holdings Ltd has 5,588,572,000 shares outstanding.
What happened to Kontafarma China Holdings Ltd’s price movement after its last earnings report?
Kontafarma China Holdings Ltd reported an EPS of -HK$0.026 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.448%.
Which hedge fund is a major shareholder of Kontafarma China Holdings Ltd?
Currently, no hedge funds are holding shares in HK:1312
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kontafarma China Holdings Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.28%
12-Months-Change
Fundamentals
Return on Equity
-69.10%
Trailing 12-Months
Asset Growth
-32.90%
Trailing 12-Months
Company Description
Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd. directs its business efforts through two principal segments: Pharmaceutical and Fitness. Its Pharmaceutical arm is responsible for the manufacturing and marketing of prescription medications and associated laboratory goods. Meanwhile, the Fitness division oversees the management of health clubs, delivers advisory services for physical well-being and health-related pursuits, and runs a franchise model to generate royalty revenue. Established on March 21, 2011, the company maintains its corporate headquarters in Hong Kong.
Technical Analysis
China National Building Material Co
―
Xinyi Glass Holdings
―
China Glass Holdings Limited
―
China Tianrui Group Cement Co., Ltd.
―
YCIH Green High-Performance Concrete Co., Ltd. Class H
―